Description |
Neticonazole is an imidazole derivative and a potent and long-acting antifungal agent. Neticonazole is also an orally active exosome biogenesis and secretion inhibitor. Neticonazole has anti-infection and anti-cancer effects[1][2][3].
|
Related Catalog |
|
Target |
Fungal [1] Exosome secretion[2]
|
In Vitro |
Neticonazole (10 µM; 48 hours; C4-2B cells) treatment decreases the levels of both Alix and Rab27a, and significantly decreases nSMase2 levels. Neticonazole causes a significant inhibition in p-ERK levels[2]. Neticonazole (0-10 µM) exhibits a potent and dose-dependent inhibition of exosome release from C4-2B cells[2]. Western Blot Analysis[2] Cell Line: C4-2B cells Concentration: 10 µM Incubation Time: 48 hours Result: Decreased the levels of both Alix and Rab27a, and significantly decreased nSMase2 levels.
|
In Vivo |
Neticonazole (1-100 ng/kg; oral gavage; daily; for 15 days; male C57BL/6 mice) treatment significantly improves the survival of intestinal dysbacteriosis (IDB) mice with colorectal cancer (CRC) xenograft tumors, likely through increasing apoptosis of CRC xenograft tumor cells[3]. Animal Model: Male C57BL/6 mice (8 weeks old) given ampicillin, neomycin, metronidazole and vancomycin, and injected with SW480 cells[3] Dosage: 1 ng/kg, 10 ng/kg and 100 ng/kg Administration: Oral gavage; daily; for 15 days Result: Significantly improved the survival of IDB mice with CRC xenograft tumors.
|
References |
[1]. Tsuboi R, et al. Hyperkeratotic chronic tinea pedis treated with neticonazole cream. Neticonazole Study Group. Int J Dermatol. 1996 May;35(5):371-3. [2]. Datta A, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25;8(1):8161. [3]. Gu L, et al. The exosome secretion inhibitor neticonazole suppresses intestinal dysbacteriosis-induced tumorigenesis of colorectal cancer. Invest New Drugs. 2020 Apr;38(2):221-228.
|